{"success":true,"data":{"pressRelease":{"id":"165243","rtpr_id":"nGNX6wdvsJ-20261009","ticker":"SGMT","exchange":"NASDAQ","all_tickers":["SGMT"],"title":"Sagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical Dermatology Conference","author":"Globe Newswire","published_at":"2026-10-09T11:00:00.575Z","article_body":"* Denifanstat showed continued improvement and sustained efficacy across all\nefficacy endpoints through 52 weeks, including 57% IGA success, 72% reduction\nin total lesions, and 77% reduction in inflammatory lesions, and was generally\nwell-tolerated\n* Clinical findings and preclinical mechanistic evidence support FASN\ninhibition as a novel oral therapeutic approach targeting key aspects of acne\npathogenesis\n* AURORA U.S. Phase 3 trial screening patients, with sites activated and IRB\napprovals in place\nFOSTER CITY, Calif., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences\nInc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing\nnovel therapeutics targeting dysfunctional metabolic and fibrotic pathways,\ntoday announced that the positive 52-week clinical results from the Phase 3\nASC40-304 open-label extension of denifanstat in patients with moderate to\nsevere acne vulgaris, conducted by license partner Ascletis BioScience Co.\nLtd. (Ascletis) in China, along with mechanistic data, will be presented at\nthe 2026 Fall Clinical Dermatology Conference taking place October 8-11, in\nLas Vegas, Nevada. Denifanstat is a once-daily oral small molecule fatty acid\nsynthase (FASN) inhibitor being developed by Ascletis as ASC40 in China\nwhere it holds an exclusive license to denifanstat, and by Sagimet in the\nrest of the world.\n\nThe Phase 3 OLE clinical trial, ASC40-304, evaluated the long-term safety of\ndenifanstat in patients with moderate to severe acne vulgaris who were\npreviously enrolled in the 12-week randomized, double-blind,\nplacebo-controlled Phase 3 ASC40-303 clinical trial. Both trials were\nconducted in China by Ascletis. 240 patients rolled over into the OLE trial,\nfor a total trial duration of up to 52 weeks; 116 of those patients had\nreceived denifanstat in the original ASC40-303 trial, and 124 patients had\nreceived placebo. Primary endpoints of the OLE evaluated safety and secondary\nendpoints evaluated efficacy, including Investigator’s Global Assessment\n(IGA) success and reduction in total lesion count and inflammatory lesion\ncount from baseline. Ascletis’ NDA submission for approval in China to the\nNational Medical Products Association (NMPA) was accepted in December 2025.\n\n2026 Fall Clinical Dermatology Conference Poster Presentation Details:\n\n Title:              Denifanstat, a fatty acid synthase inhibitor, achieved significant clinical improvement in moderate-to-severe acne vulgaris: a review of mechanistic and clinical data   \n Presenting author:  Julie Harper , MD, Founding Director and past President of the American Acne and Rosacea Society, Dermatology and Skin Care Center of Birmingham in Birmingham, Alabama  \n Date:               October 8 - 11, 2026                                                                                                                                                     \n Location:           The Wynn Hotel, Las Vegas, Nevada                                                                                                                                        \n Key Presentation Highlights : * FASN inhibition reduced sebum lipids in human sebocytes in vitro and in participants of clinical trials in vivo.                                             \n * Denifanstat, an oral FASN inhibitor, significantly improved IGA scores and reduced lesion counts in patients with moderate-to-severe acne compared to placebo over 12 weeks with significant improvements observed as early as 4 weeks and continued clinical improvements through 52 weeks.  \n * Together, the clinical findings and preclinical mechanistic evidence support FASN inhibition as a novel oral therapeutic approach for acne that targets key aspects of acne pathogenesis by reducing de novo lipogenesis, sebum production, and inflammation. \n\n“The data being presented at the Fall Clinical Dermatology Conference\nhighlight the potential and novel role of FASN inhibition to treat patients\nand families living with acne,” said David Happel, Chief Executive Officer\nof Sagimet. “Denifanstat has demonstrated significant and sustained\nimprovements in moderate to severe acne through 52 weeks of treatment. With\nAURORA sites activated and patient screening beginning this month, we are\nexcited to be advancing denifanstat into our U.S. Phase 3 program.”\n\nAbout the Ascletis Phase 3 Clinical Trial and Open-Label Extension\n\nASC40-303 (NCT06192264) was a randomized, double-blind, placebo-controlled\n12-week Phase 3 clinical trial of denifanstat in 480 patients with moderate to\nsevere acne vulgaris, conducted in China by Ascletis. Patients were randomized\n1:1 to denifanstat 50 mg or placebo once daily. Denifanstat met all primary\nand secondary endpoints and was generally well-tolerated.\n\nASC40-304 (NCT06248008) was a multi-center, open-label Phase 3 extension\nevaluating the long-term safety of denifanstat in patients with moderate to\nsevere acne vulgaris who were previously enrolled in the double-blind,\nrandomized, placebo-controlled 12-week Phase 3 ASC40-303 trial. This\nopen-label Phase 3 trial enrolled 240 subjects who received oral denifanstat\n50 mg once daily for up to 40 weeks. Subjects who were originally randomized\nto denifanstat in ASC40-303 trial had a total of up to 52 weeks of denifanstat\nexposure. Primary endpoints evaluated safety, and secondary endpoints\nevaluated efficacy, including the number of patients with IGA success and the\nreduction in total lesion count and inflammatory lesion count from baseline\nfor up to 52 weeks of denifanstat treatment. Denifanstat was generally\nwell-tolerated. Subjects treated with denifanstat showed improvements in all\nefficacy endpoints (secondary endpoints of the trial) beyond those observed at\n12 weeks. \n\nAbout the AURORA Phase 3 Clinical Trial\n\nThe AURORA (NCT07863193) multi-center, randomized, double-blind,\nplacebo-controlled Phase 3 clinical trial of denifanstat in moderate to severe\nacne is intended to enroll approximately 800 U.S. patients aged 12 years and\nolder, of which 450 are expected to be adolescents aged 12 to 17 years.\nPatients will be randomized 2:1 to receive denifanstat 50 mg or placebo once\ndaily for 12 weeks. The trial will have three co-primary endpoints that will\nbe assessed at week 12: the proportion of patients achieving treatment success\nin a global assessment score, defined as at least a 2-point reduction from\nbaseline with a score of 0 (clear) or 1 (almost clear); absolute change in\ninflammatory skin lesion counts from baseline; and absolute change in\nnon-inflammatory skin lesion counts from baseline. A subset of approximately\n530 patients completing the double-blind period will be eligible to enter a\n40-week open-label extension evaluating the long-term safety of denifanstat.\n\nAbout Denifanstat\n\nDenifanstat is an oral, once-daily FASN inhibitor in development for the\ntreatment of moderate to severe acne. In trials conducted by Sagimet’s\nlicense partner, Ascletis BioScience Co. Ltd. (Ascletis) in China,\ndenifanstat met all primary and secondary endpoints in a 12 week randomized,\ndouble-blind Phase 3 clinical trial in moderate to severe acne vulgaris and\nwas generally well-tolerated and showed improvements in all efficacy endpoints\nmeasured at 52 weeks (secondary endpoints of the trial) in an open-label\nextension clinical trial evaluating denifanstat’s long-term safety in\npatients with moderate to severe acne. Denifanstat is being developed\nby Ascletis as ASC40 for acne in China and by Sagimet in the rest of\nworld.\n\nAbout Acne\n\nAcne is one of the most common skin conditions in the U.S., with\napproximately 50 million Americans affected annually and more than 5 million\nseeking medical treatment for acne each year. Acne affects around 85% of\npersons between the ages of 12 and 24. Moderate to severe acne accounts for\n20% of acne sufferers, or approximately 10 million people in\nthe U.S. annually. There is no cure for acne, and due to its pathology, most\npatients require chronic management and multiple annual courses of treatment\nfor flare control.\n\nAbout Sagimet Biosciences\n\nSagimet is a clinical-stage biopharmaceutical company developing novel FASN\ninhibitors designed to target dysfunctional metabolic and fibrotic pathways in\nconditions resulting from the overproduction of the fatty acid, palmitate.\nFASN is a regulator of lipid synthesis, a key pathway implicated in multiple\ndiseases, such as acne, MASH and certain FASN-dependent tumor types. For\nadditional information about Sagimet, please visit www.sagimet.com.\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements within the meaning of,\nand made pursuant to the safe harbor provisions of, The Private Securities\nLitigation Reform Act of 1995. All statements contained in this press release,\nother than statements of historical facts or statements that relate to present\nfacts or current conditions, including but not limited to, statements\nregarding the expected timing of the presentation of data from ongoing\nclinical trials, Sagimet’s clinical development plans and related timelines\nand anticipated development milestones, are forward-looking statements. These\nstatements involve known and unknown risks, uncertainties and other important\nfactors that may cause Sagimet’s actual results, performance or achievements\nto be materially different from any future results, performance or\nachievements expressed or implied by the forward-looking statements. In some\ncases, these statements can be identified by terms such as “may,”\n“might,” “will,” “should,” “expect,” “plan,” “aim,”\n“seek,” “anticipate,” “could,” “intend,” “target,”\n“project,” “contemplate,” “believe,” “estimate,”\n“predict,” “forecast,” “potential” or “continue” or the\nnegative of these terms or other similar expressions. The forward-looking\nstatements in this press release are only predictions. Sagimet has based these\nforward-looking statements largely on its current expectations and projections\nabout future events and financial trends that Sagimet believes may affect its\nbusiness, financial condition and results of operations. These forward-looking\nstatements speak only as of the date of this press release and are subject to\na number of risks, uncertainties and assumptions, some of which cannot be\npredicted or quantified and some of which are beyond Sagimet’s control,\nincluding, among others: the clinical development and therapeutic potential of\ndenifanstat, TVB-3567 or any other drug candidates or combination therapies\ndeveloped by Sagimet; Sagimet’s ability to advance drug candidates into and\nsuccessfully complete clinical trials within anticipated timelines;\nSagimet’s relationship with Ascletis, and the success of its development and\nregistration efforts for denifanstat; the accuracy of Sagimet’s estimates\nregarding its capital requirements and Sagimet’s ability to maintain and\nsuccessfully enforce adequate intellectual property protection. These and\nother risks and uncertainties are described more fully in the “Risk\nFactors” section of Sagimet’s most recent filings with the Securities and\nExchange Commission and available at www.sec.gov. You should not rely on these\nforward-looking statements as predictions of future events. The events and\ncircumstances reflected in these forward-looking statements may not be\nachieved or occur, and actual results could differ materially from those\nprojected in the forward-looking statements. Moreover, Sagimet operates in a\ndynamic industry and economy. New risk factors and uncertainties may emerge\nfrom time to time, and it is not possible for management to predict all risk\nfactors and uncertainties that Sagimet may face. Except as required by\napplicable law, Sagimet does not plan to publicly update or revise any\nforward-looking statements contained herein, whether as a result of any new\ninformation, future events, changed circumstances or otherwise.\n\nInvestor Contact:\nJoyce Allaire \nLifeSci Advisors \nJAllaire@LifeSciAdvisors.com\n\nMedia Contact:\nMaggie Whitney\nLifeSci Communications\nmwhitney@lifescicomms.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/e944daed-3f71-402b-bb23-82149e5c0d26)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX6wdvsJ-20261009","title":"Sagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical Dermatology Conference","author":"Globe Newswire","ticker":"SGMT","created":"2026-10-09T11:00:00.575Z","tickers":["SGMT"],"exchange":"NASDAQ","article_body":"* Denifanstat showed continued improvement and sustained efficacy across all\nefficacy endpoints through 52 weeks, including 57% IGA success, 72% reduction\nin total lesions, and 77% reduction in inflammatory lesions, and was generally\nwell-tolerated\n* Clinical findings and preclinical mechanistic evidence support FASN\ninhibition as a novel oral therapeutic approach targeting key aspects of acne\npathogenesis\n* AURORA U.S. Phase 3 trial screening patients, with sites activated and IRB\napprovals in place\nFOSTER CITY, Calif., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences\nInc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing\nnovel therapeutics targeting dysfunctional metabolic and fibrotic pathways,\ntoday announced that the positive 52-week clinical results from the Phase 3\nASC40-304 open-label extension of denifanstat in patients with moderate to\nsevere acne vulgaris, conducted by license partner Ascletis BioScience Co.\nLtd. (Ascletis) in China, along with mechanistic data, will be presented at\nthe 2026 Fall Clinical Dermatology Conference taking place October 8-11, in\nLas Vegas, Nevada. Denifanstat is a once-daily oral small molecule fatty acid\nsynthase (FASN) inhibitor being developed by Ascletis as ASC40 in China\nwhere it holds an exclusive license to denifanstat, and by Sagimet in the\nrest of the world.\n\nThe Phase 3 OLE clinical trial, ASC40-304, evaluated the long-term safety of\ndenifanstat in patients with moderate to severe acne vulgaris who were\npreviously enrolled in the 12-week randomized, double-blind,\nplacebo-controlled Phase 3 ASC40-303 clinical trial. Both trials were\nconducted in China by Ascletis. 240 patients rolled over into the OLE trial,\nfor a total trial duration of up to 52 weeks; 116 of those patients had\nreceived denifanstat in the original ASC40-303 trial, and 124 patients had\nreceived placebo. Primary endpoints of the OLE evaluated safety and secondary\nendpoints evaluated efficacy, including Investigator’s Global Assessment\n(IGA) success and reduction in total lesion count and inflammatory lesion\ncount from baseline. Ascletis’ NDA submission for approval in China to the\nNational Medical Products Association (NMPA) was accepted in December 2025.\n\n2026 Fall Clinical Dermatology Conference Poster Presentation Details:\n\n Title:              Denifanstat, a fatty acid synthase inhibitor, achieved significant clinical improvement in moderate-to-severe acne vulgaris: a review of mechanistic and clinical data   \n Presenting author:  Julie Harper , MD, Founding Director and past President of the American Acne and Rosacea Society, Dermatology and Skin Care Center of Birmingham in Birmingham, Alabama  \n Date:               October 8 - 11, 2026                                                                                                                                                     \n Location:           The Wynn Hotel, Las Vegas, Nevada                                                                                                                                        \n Key Presentation Highlights : * FASN inhibition reduced sebum lipids in human sebocytes in vitro and in participants of clinical trials in vivo.                                             \n * Denifanstat, an oral FASN inhibitor, significantly improved IGA scores and reduced lesion counts in patients with moderate-to-severe acne compared to placebo over 12 weeks with significant improvements observed as early as 4 weeks and continued clinical improvements through 52 weeks.  \n * Together, the clinical findings and preclinical mechanistic evidence support FASN inhibition as a novel oral therapeutic approach for acne that targets key aspects of acne pathogenesis by reducing de novo lipogenesis, sebum production, and inflammation. \n\n“The data being presented at the Fall Clinical Dermatology Conference\nhighlight the potential and novel role of FASN inhibition to treat patients\nand families living with acne,” said David Happel, Chief Executive Officer\nof Sagimet. “Denifanstat has demonstrated significant and sustained\nimprovements in moderate to severe acne through 52 weeks of treatment. With\nAURORA sites activated and patient screening beginning this month, we are\nexcited to be advancing denifanstat into our U.S. Phase 3 program.”\n\nAbout the Ascletis Phase 3 Clinical Trial and Open-Label Extension\n\nASC40-303 (NCT06192264) was a randomized, double-blind, placebo-controlled\n12-week Phase 3 clinical trial of denifanstat in 480 patients with moderate to\nsevere acne vulgaris, conducted in China by Ascletis. Patients were randomized\n1:1 to denifanstat 50 mg or placebo once daily. Denifanstat met all primary\nand secondary endpoints and was generally well-tolerated.\n\nASC40-304 (NCT06248008) was a multi-center, open-label Phase 3 extension\nevaluating the long-term safety of denifanstat in patients with moderate to\nsevere acne vulgaris who were previously enrolled in the double-blind,\nrandomized, placebo-controlled 12-week Phase 3 ASC40-303 trial. This\nopen-label Phase 3 trial enrolled 240 subjects who received oral denifanstat\n50 mg once daily for up to 40 weeks. Subjects who were originally randomized\nto denifanstat in ASC40-303 trial had a total of up to 52 weeks of denifanstat\nexposure. Primary endpoints evaluated safety, and secondary endpoints\nevaluated efficacy, including the number of patients with IGA success and the\nreduction in total lesion count and inflammatory lesion count from baseline\nfor up to 52 weeks of denifanstat treatment. Denifanstat was generally\nwell-tolerated. Subjects treated with denifanstat showed improvements in all\nefficacy endpoints (secondary endpoints of the trial) beyond those observed at\n12 weeks. \n\nAbout the AURORA Phase 3 Clinical Trial\n\nThe AURORA (NCT07863193) multi-center, randomized, double-blind,\nplacebo-controlled Phase 3 clinical trial of denifanstat in moderate to severe\nacne is intended to enroll approximately 800 U.S. patients aged 12 years and\nolder, of which 450 are expected to be adolescents aged 12 to 17 years.\nPatients will be randomized 2:1 to receive denifanstat 50 mg or placebo once\ndaily for 12 weeks. The trial will have three co-primary endpoints that will\nbe assessed at week 12: the proportion of patients achieving treatment success\nin a global assessment score, defined as at least a 2-point reduction from\nbaseline with a score of 0 (clear) or 1 (almost clear); absolute change in\ninflammatory skin lesion counts from baseline; and absolute change in\nnon-inflammatory skin lesion counts from baseline. A subset of approximately\n530 patients completing the double-blind period will be eligible to enter a\n40-week open-label extension evaluating the long-term safety of denifanstat.\n\nAbout Denifanstat\n\nDenifanstat is an oral, once-daily FASN inhibitor in development for the\ntreatment of moderate to severe acne. In trials conducted by Sagimet’s\nlicense partner, Ascletis BioScience Co. Ltd. (Ascletis) in China,\ndenifanstat met all primary and secondary endpoints in a 12 week randomized,\ndouble-blind Phase 3 clinical trial in moderate to severe acne vulgaris and\nwas generally well-tolerated and showed improvements in all efficacy endpoints\nmeasured at 52 weeks (secondary endpoints of the trial) in an open-label\nextension clinical trial evaluating denifanstat’s long-term safety in\npatients with moderate to severe acne. Denifanstat is being developed\nby Ascletis as ASC40 for acne in China and by Sagimet in the rest of\nworld.\n\nAbout Acne\n\nAcne is one of the most common skin conditions in the U.S., with\napproximately 50 million Americans affected annually and more than 5 million\nseeking medical treatment for acne each year. Acne affects around 85% of\npersons between the ages of 12 and 24. Moderate to severe acne accounts for\n20% of acne sufferers, or approximately 10 million people in\nthe U.S. annually. There is no cure for acne, and due to its pathology, most\npatients require chronic management and multiple annual courses of treatment\nfor flare control.\n\nAbout Sagimet Biosciences\n\nSagimet is a clinical-stage biopharmaceutical company developing novel FASN\ninhibitors designed to target dysfunctional metabolic and fibrotic pathways in\nconditions resulting from the overproduction of the fatty acid, palmitate.\nFASN is a regulator of lipid synthesis, a key pathway implicated in multiple\ndiseases, such as acne, MASH and certain FASN-dependent tumor types. For\nadditional information about Sagimet, please visit www.sagimet.com.\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements within the meaning of,\nand made pursuant to the safe harbor provisions of, The Private Securities\nLitigation Reform Act of 1995. All statements contained in this press release,\nother than statements of historical facts or statements that relate to present\nfacts or current conditions, including but not limited to, statements\nregarding the expected timing of the presentation of data from ongoing\nclinical trials, Sagimet’s clinical development plans and related timelines\nand anticipated development milestones, are forward-looking statements. These\nstatements involve known and unknown risks, uncertainties and other important\nfactors that may cause Sagimet’s actual results, performance or achievements\nto be materially different from any future results, performance or\nachievements expressed or implied by the forward-looking statements. In some\ncases, these statements can be identified by terms such as “may,”\n“might,” “will,” “should,” “expect,” “plan,” “aim,”\n“seek,” “anticipate,” “could,” “intend,” “target,”\n“project,” “contemplate,” “believe,” “estimate,”\n“predict,” “forecast,” “potential” or “continue” or the\nnegative of these terms or other similar expressions. The forward-looking\nstatements in this press release are only predictions. Sagimet has based these\nforward-looking statements largely on its current expectations and projections\nabout future events and financial trends that Sagimet believes may affect its\nbusiness, financial condition and results of operations. These forward-looking\nstatements speak only as of the date of this press release and are subject to\na number of risks, uncertainties and assumptions, some of which cannot be\npredicted or quantified and some of which are beyond Sagimet’s control,\nincluding, among others: the clinical development and therapeutic potential of\ndenifanstat, TVB-3567 or any other drug candidates or combination therapies\ndeveloped by Sagimet; Sagimet’s ability to advance drug candidates into and\nsuccessfully complete clinical trials within anticipated timelines;\nSagimet’s relationship with Ascletis, and the success of its development and\nregistration efforts for denifanstat; the accuracy of Sagimet’s estimates\nregarding its capital requirements and Sagimet’s ability to maintain and\nsuccessfully enforce adequate intellectual property protection. These and\nother risks and uncertainties are described more fully in the “Risk\nFactors” section of Sagimet’s most recent filings with the Securities and\nExchange Commission and available at www.sec.gov. You should not rely on these\nforward-looking statements as predictions of future events. The events and\ncircumstances reflected in these forward-looking statements may not be\nachieved or occur, and actual results could differ materially from those\nprojected in the forward-looking statements. Moreover, Sagimet operates in a\ndynamic industry and economy. New risk factors and uncertainties may emerge\nfrom time to time, and it is not possible for management to predict all risk\nfactors and uncertainties that Sagimet may face. Except as required by\napplicable law, Sagimet does not plan to publicly update or revise any\nforward-looking statements contained herein, whether as a result of any new\ninformation, future events, changed circumstances or otherwise.\n\nInvestor Contact:\nJoyce Allaire \nLifeSci Advisors \nJAllaire@LifeSciAdvisors.com\n\nMedia Contact:\nMaggie Whitney\nLifeSci Communications\nmwhitney@lifescicomms.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/e944daed-3f71-402b-bb23-82149e5c0d26)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-09T11:00:00.847453533Z","server_sent_at_ms":1791543600847},"received_at":"2026-10-09T11:00:00.898Z","source_url":null},"analysis":{"id":"153639","press_release_id":"165243","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"clinical_trial","narrative":"Sagimet said positive 52-week results from Ascletis' Phase 3 open-label extension of denifanstat in moderate-to-severe acne will be presented at the 2026 Fall Clinical Dermatology Conference.\n\nThe data showed 57% IGA success, 72% total lesion reduction and 77% inflammatory lesion reduction at 52 weeks, with denifanstat generally well-tolerated. Ascletis' China NDA was accepted in December 2025.\n\nFor Sagimet directly, the U.S. AURORA Phase 3 trial (~800 patients) has sites activated and patient screening underway, advancing the company's own pivotal program.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Sustained 52-week acne efficacy plus U.S. AURORA Phase 3 screening kickoff de-risks denifanstat's Western path."},"keyFigures":{"drugName":"denifanstat (ASC40)","phaseOfTrial":"Phase 3","customDimensions":{"iga_success":"57%","ole_patients":240,"asc40_303_patients":480,"total_lesion_reduction":"72%","aurora_enrollment_target":800,"inflammatory_lesion_reduction":"77%"}},"quotedText":"Denifanstat has demonstrated significant and sustained improvements in moderate to severe acne through 52 weeks of treatment. With AURORA sites activated and patient screening beginning this month, we are excited to be advancing denifanstat into our U.S. Phase 3 program.","namedEntities":{"people":[{"name":"David Happel","role":"CEO of Sagimet Biosciences"},{"name":"Julie Harper","role":"presenting author, MD, Dermatology and Skin Care Center of Birmingham"}],"products":["denifanstat","ASC40","TVB-3567"],"companies":[{"name":"Sagimet Biosciences Inc.","ticker":"SGMT","relationship":"filer"},{"name":"Ascletis BioScience Co. Ltd.","relationship":"license partner conducting China trials"},{"name":"LifeSci Advisors","relationship":"investor relations contact"}],"dollarAmounts":[]},"materialImpact":{"score":3,"reasoning":"Positive 52-week open-label extension data supporting denifanstat in acne, plus confirmation that Sagimet's own U.S. AURORA Phase 3 trial is screening patients. Results are from partner Ascletis' China OLE (secondary endpoints, open-label) and were already partly known, limiting impact to moderate."},"tickerRelevance":{"others":[],"primary":"SGMT"},"globalImportance":35,"audienceRelevance":25,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap clinical-stage biotech","eventGravity":"conference data presentation of already-released OLE results plus U.S. Phase 3 activation","openLabelCaveat":"secondary-endpoint, open-label data limits regulatory weight"}},"event_type":"clinical_trial","event_type_secondary":null,"sentiment":"bullish","material_impact_score":3,"narrative":"Sagimet said positive 52-week results from Ascletis' Phase 3 open-label extension of denifanstat in moderate-to-severe acne will be presented at the 2026 Fall Clinical Dermatology Conference.\n\nThe data showed 57% IGA success, 72% total lesion reduction and 77% inflammatory lesion reduction at 52 weeks, with denifanstat generally well-tolerated. Ascletis' China NDA was accepted in December 2025.\n\nFor Sagimet directly, the U.S. AURORA Phase 3 trial (~800 patients) has sites activated and patient screening underway, advancing the company's own pivotal program.","key_figures":{"drugName":"denifanstat (ASC40)","phaseOfTrial":"Phase 3","customDimensions":{"iga_success":"57%","ole_patients":240,"asc40_303_patients":480,"total_lesion_reduction":"72%","aurora_enrollment_target":800,"inflammatory_lesion_reduction":"77%"}},"named_entities":{"people":[{"name":"David Happel","role":"CEO of Sagimet Biosciences"},{"name":"Julie Harper","role":"presenting author, MD, Dermatology and Skin Care Center of Birmingham"}],"products":["denifanstat","ASC40","TVB-3567"],"companies":[{"name":"Sagimet Biosciences Inc.","ticker":"SGMT","relationship":"filer"},{"name":"Ascletis BioScience Co. Ltd.","relationship":"license partner conducting China trials"},{"name":"LifeSci Advisors","relationship":"investor relations contact"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-09T11:00:07.129Z","global_importance":35,"audience_relevance":25,"importance_components":{"tickerTier":"small-cap clinical-stage biotech","eventGravity":"conference data presentation of already-released OLE results plus U.S. Phase 3 activation","openLabelCaveat":"secondary-endpoint, open-label data limits regulatory weight"}},"durationMs":6191,"modelName":"glm-5.3-flashx"}}